Eos Energy Enterprises Inc vs McKesson Corporation — how do they compare? Eos Energy Enterprises Inc trades at $2.84 (market cap $1.13B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 93.9× Eos Energy Enterprises Inc's market cap, and McKesson Corporation pays a 0.41% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and McKesson Corporation for 74 Days on average.
| EOSE | MCK | |
|---|---|---|
Market Cap | $1.13B | $106.14B |
Volume | 17,918,777 | 794,405 |
Sector | Industrials | Health |
52-Week High | $19.19 | $995.69 |
52-Week Low | $2.77 | $725.17 |
Typical Hold Time | 16 Days | 74 Days |
Enterprise Value | $1.47B | $112.67B |
Dividend Yield | — | 0.41% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.
The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →